Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen F Pirollo

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Trends in Biotechnology|August 30, 2008
Does a targeting ligand influence nanoparticle tumor localization or uptake?Kathleen F Pirollo, Esther H Chang
Cancer Research|March 5, 2008
Targeted delivery of small interfering RNA: approaching effective cancer therapiesKathleen F Pirollo, Esther H Chang
Current Protocols in Cell Biology|June 11, 2015
Isolation and Culturing of Glioma Cancer Stem CellsSang-Soo Kim, Kathleen F Pirollo, Esther H Chang
Academic Radiology|April 7, 2009
Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastasesMatthew Freedman, Esther H Chang, Qi Zhou, et al.
Pharmacology & Therapeutics|June 14, 2003
Antisense therapeutics: from theory to clinical practiceKathleen F Pirollo, Antonina Rait, Leanne S Sleer, et al.
Viruses|April 23, 2022
<i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19Joe B Harford, Sang Soo Kim, Kathleen F Pirollo, et al.
Biochemical and Biophysical Research Communications|June 28, 2015
Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicineSang-Soo Kim, Joe B Harford, Kathleen F Pirollo, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|September 22, 2014
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiformeSang-Soo Kim, Antonina Rait, Eric Kim, et al.
Molecular Medicine (Cambridge, Mass.)|November 19, 2002
Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levelsAntonina S Rait, Kathleen F Pirollo, Laiman Xiang, et al.
Annals of the New York Academy of Sciences|January 31, 2004
HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agentsAntonina S Rait, Kathleen F Pirollo, David Ulick, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Trends in Biotechnology|August 30, 2008
Does a targeting ligand influence nanoparticle tumor localization or uptake?Kathleen F Pirollo, Esther H Chang
Cancer Research|March 5, 2008
Targeted delivery of small interfering RNA: approaching effective cancer therapiesKathleen F Pirollo, Esther H Chang
Current Protocols in Cell Biology|June 11, 2015
Isolation and Culturing of Glioma Cancer Stem CellsSang-Soo Kim, Kathleen F Pirollo, Esther H Chang
Academic Radiology|April 7, 2009
Nanodelivery of MRI contrast agent enhances sensitivity of detection of lung cancer metastasesMatthew Freedman, Esther H Chang, Qi Zhou, et al.
Pharmacology & Therapeutics|June 14, 2003
Antisense therapeutics: from theory to clinical practiceKathleen F Pirollo, Antonina Rait, Leanne S Sleer, et al.
Viruses|April 23, 2022
<i>TP53</i> Gene Therapy as a Potential Treatment for Patients with COVID-19Joe B Harford, Sang Soo Kim, Kathleen F Pirollo, et al.
Biochemical and Biophysical Research Communications|June 28, 2015
Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicineSang-Soo Kim, Joe B Harford, Kathleen F Pirollo, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|September 22, 2014
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiformeSang-Soo Kim, Antonina Rait, Eric Kim, et al.
Molecular Medicine (Cambridge, Mass.)|November 19, 2002
Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levelsAntonina S Rait, Kathleen F Pirollo, Laiman Xiang, et al.
Annals of the New York Academy of Sciences|January 31, 2004
HER-2-targeted antisense oligonucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agentsAntonina S Rait, Kathleen F Pirollo, David Ulick, et al.
Pageof 4